Clinical

Dataset Information

0

A Multicenter single arm Phase II clinical trial of the second-line treatment with FOLFIRI plus panitumumab after failure of the first-line treatment with FOLFOX plus panitumumab for advanced and/or recurrent RAS wild-type colorectal cancer with special reference to the changes in biomarker expression examined by a liquid biopsy and its effect on the refractory tumor


ABSTRACT: Interventions: Second-line treatment with FOLFIRI plus panitumumab after failure of the first-line treatment with FOLFOX plus panitumumab for advanced and/or recurrent RAS wild-type colorectal cancer with special reference to the changes in biomarker expression examined by a liquid biopsy and its effect on the refractory tumor Primary outcome(s): 6-month progression-free survival (PFS) rate * Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2642034 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2019-01-23 | GSE102995 | GEO
| S-EPMC5784655 | biostudies-literature
2016-05-05 | E-MTAB-3548 | biostudies-arrayexpress
| S-EPMC6192615 | biostudies-literature
| 2369067 | ecrin-mdr-crc
| 2386782 | ecrin-mdr-crc
2021-11-12 | GSE181792 | GEO
| 2365936 | ecrin-mdr-crc
| PRJEB67820 | ENA
| 2614860 | ecrin-mdr-crc